高级检索
当前位置: 首页 > 详情页

Tianma Gouteng Yin Formula for treating primary hypertension

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Chinese Univ Hong Kong, Sch Chinese Med, Shatin, Hong Kong, Peoples R China [2]Guangzhou Med Univ, Dept Acupuncture, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China [3]Yixing Peoples Hosp, Dept Chinese Med, Yixing, Peoples R China [4]China Japan Friendship Hosp, Dept Integrated Med Cardiovasc Dis, Beijing, Peoples R China [5]Chinese Acad Med Sci, Beijing 100730, Peoples R China [6]Peking Union Med Coll, Beijing 100021, Peoples R China
出处:
ISSN:

摘要:
Background Tianma Gouteng Yin Formula (TGYF) is widely used to treat hypertension-related symptoms in clinical practice in East Asia. It has been shown to have a blood pressure lowering effect, reducing total cholesterol, improving clinical symptoms and quality of life, and preventing the occurrence of stroke in hypertensive patients. Understanding the effect of Tianma Gouteng Yin Formula on blood pressure, quality of life and cardiovascular risk factors could be valuable for the management of high blood pressure. Objectives To assess the efficacy and safety of Tianma Gouteng Yin Formula for treating primary hypertension compared to placebo or no treatment. S ear c h methods English databases including Cochrane Central (CCTR), MEDLINE, EMBASE, AMED, CINAHL, IPA, and the Hypertension Group Specialised Register were searched up to July 2011. Chinese databases including Chinese Biomedical Database, TCMonline, Chinese Dissertation Database, CMAC and the Index to Chinese Periodical Literature were searched up to April 2010. Selection criteria Randomised and quasi-randomised controlled trials that compared TGYF with no treatment or placebo for primary hypertension. Data collection and analysis No study was identified which met the inclusion criteria for this review. Main results No study was identified which met the inclusion criteria for this review. Authors' conclusions As no trials could be identified, no conclusions can be made about the role of TGYF in the treatment of primary hypertension. Well-designed randomized controlled studies need to be conducted and published.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2011]版:
大类 | 2 区 医学
小类 | 2 区 医学:内科
最新[2025]版
大类 | 2 区 医学
小类 | 2 区 医学:内科
JCR分区:
出版当年[2010]版:
Q1 MEDICINE, GENERAL & INTERNAL
最新[2024]版:
Q1 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2024版] 最新五年平均[2021-2025] 出版当年[2010版] 出版当年五年平均[2006-2010] 出版前一年[2009版] 出版后一年[2011版]

第一作者:
第一作者单位: [1]Chinese Univ Hong Kong, Sch Chinese Med, Shatin, Hong Kong, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:819 更新日期:2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)